Drug intelligence / Profile preview

RCT002

Development stage: Preclinical
Lead developer: Roca Therapeutics
Modality: Small Molecules
Administration: Topical, Ophthalmic

Overview

RCT002 is a first-in-class small molecule drug developed by Roca Therapeutics for the topical treatment of severe ocular diseases, including radiation-induced maculopathy, macular dystrophy, and glaucoma. It is designed to be administered non-invasively as an eye drop. The mechanism of action involves blocking resistant angiogenesis (the formation of new blood vessels that are unresponsive to VEGF inhibition), oxidative stress, inflammation, and fibrosis in the retina. This VEGF-independent approach aims to address disease pathways not targeted by current anti-VEGF therapies[1][4]. RCT002 is currently in preclinical development.

Targets

EIF4A2 (Eukaryotic translation initiation factor 4A2)DDX3X (DEAD-box helicase 3 X-linked)EIF4A1 (Eukaryotic translation initiation factor 4A1)

Beyond the preview

Go deeper on RCT002.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RCT002.

Explore the full profile